UB Paderborn / Katalog / Suche / in CDI

Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii526-viii527

2018

Volltextzugriff (PDF)

Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

Annals of oncology, 2018-11, Vol.29, p.ix161-ix161

2018

Volltextzugriff (PDF)

1103P Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: A real-world setting

Annals of oncology, 2022-09, Vol.33, p.S1055-S1056

2022

Volltextzugriff (PDF)

448PD Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

448PD Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation

Annals of oncology, 2016-12, Vol.27, p.ix144-ix144

2016

Volltextzugriff (PDF)

473P Driver oncogene status in early-emerging lung adenocarcinoma

Annals of oncology, 2015-12, Vol.26, p.ix125-ix125

2015

Volltextzugriff (PDF)

455P Differential crizotinib response duration among ALK fusion variants in ALK-positive NSCLC

Annals of oncology, 2015-12, Vol.26, p.ix125-ix125

2015

Volltextzugriff (PDF)

521PReal-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

1455PComparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1321PIMAGING CHARACTERISTICS ASSOCIATED WITH DRIVER MUTATIONS IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv464-iv465

2014

Volltextzugriff (PDF)

Imaging Characteristics Associated with Driver Mutations in Patients with Non-Small-Cell Lung Cancer

Annals of oncology, 2014-09, Vol.25, p.iv464

2014

Volltextzugriff (PDF)

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Annals of oncology, 2015-07, Vol.26 (7), p.1372-1377

2015

Volltextzugriff (PDF)

239P Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy

Annals of oncology, 2023-11, Vol.34, p.S1566

2023

Volltextzugriff (PDF)

143P Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma

Annals of oncology, 2022-11, Vol.33, p.S1488-S1488

2022

Volltextzugriff (PDF)

254TiP Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial

Annals of oncology, 2023-11, Vol.34, p.S1571

2023

Volltextzugriff (PDF)

1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial

Annals of oncology, 2023-10, Vol.34, p.S975-S976

2023

Volltextzugriff (PDF)

1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial

Annals of oncology, 2022-09, Vol.33, p.S1168

2022

Volltextzugriff (PDF)

617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project

Annals of oncology, 2021-09, Vol.32, p.S656-S656

2021

Volltextzugriff (PDF)

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-11, Vol.33, p.S1495-S1495

2022

Volltextzugriff (PDF)

956PRandomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

956P - Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of oncology, 2019-10, Vol.30, p.v386-v387

2019

Volltextzugriff (PDF)

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of oncology, 2019-10, Vol.30, p.v386-v387

2019

Volltextzugriff (PDF)

1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-09, Vol.33, p.S1160

2022

Volltextzugriff (PDF)

Cabazitaxel plus prednisolone with primary prophylaxis with pegfilgrastim (PEG) in Japanese patients with metastatic castration-resistant prostate cancer: An open label prospective phase 2 study

Annals of oncology, 2017-11, Vol.28, p.x160-x161

2017

Volltextzugriff (PDF)

Pulmonary Blastoma with Brain Metastasis Treated with Surgical Resection and Whole Brain Irradiation

Annals of oncology, 2013-11, Vol.24, p.ix93

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

1103P Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: A real-world setting

448PD Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation

448PD Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation

473P Driver oncogene status in early-emerging lung adenocarcinoma

455P Differential crizotinib response duration among ALK fusion variants in ALK-positive NSCLC

521PReal-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation

1455PComparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC

1321PIMAGING CHARACTERISTICS ASSOCIATED WITH DRIVER MUTATIONS IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER

Imaging Characteristics Associated with Driver Mutations in Patients with Non-Small-Cell Lung Cancer

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

239P Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy

143P Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma

254TiP Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial

1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial

1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial

617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

956PRandomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

956P - Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cabazitaxel plus prednisolone with primary prophylaxis with pegfilgrastim (PEG) in Japanese patients with metastatic castration-resistant prostate cancer: An open label prospective phase 2 study

Pulmonary Blastoma with Brain Metastasis Treated with Surgical Resection and Whole Brain Irradiation

Aktive Filter

Suchergebnisse filtern